Part
01
of three
Part
01
Japanese Growth Markets: Smart Robots, Biopharmaceuticals, Life Sciences
Japan is poised for growth opportunities in the industry of smart robots, biopharmaceuticals, and life sciences. Japan is already a market leader in these segments and government is further trying to enhance the growth opportunities of these industries by marketing various programs such as National Strategic Special Zones, tax benefits, New Robot Strategy, and others to retain their leadership.
SMART ROBOT MARKET
- Japan ranks number one in robot operations and more than 50% of robots are manufactured in Japan. Japan has one of the largest number of service robot manufacturers (4th place) in the world.
1. Market Size and Growth Rate
- Japan smart robots are categorized under industrial robots and services. It has a growth rate of 13.9%.
- Japan industrial robots sales increased by 34% and exports are sold thrice when compared to domestic sales.
- According to the Japan Robot Association (JARA), 168,342 smart robots were produced in 2018 which account for 744,444 million yen (USD 6,917,931,981) with a growth of 4.7% compared to 2017.
- In 2017, Japan smart robots export growth rate increased by 28.9%.
2. Growth Factors and Opportunities
- Factors influencing growth of smart robots sector in Japan includes cultural influences such as Manga comics, historic robot adoption, labor shortages, increased stats of aged generation, and government promotional activities such as New Robot Strategy.
- New Robot Strategy was launched in 2015 by the government of Japan to improve opportunities for robot production which aimed at encouraging investments around 100 billion yen by public and private sectors and planned to expand up to 2.4 trillion yen by 2020.
- Japan government also proposed a new robot test field at Fukushima with the aim of reducing the cost of producing robots.
- Major sectors of smart robot sales include material handling robots and robots in the painting category.
BIOPHARMACEUTICALS MARKET
- Japan has taken second place in the biopharmaceuticals market (Biologics) across the globe. About 70% of Japan biopharmaceuticals market was dominated by foreign companies.
1. Market Size and Growth Rate
- As of 2018, Japan biopharmaceuticals market had a growth rate of 7.5%.
- In 2020, Japan biopharmaceuticals market is projected to reach 500 billion yen (USD 4,646,000,000).
2. Growth Factors and Opportunities
- Biopharmaceuticals contribute to 17% of healthcare expenses in Japan.
- The government recently launched Honebuto Policy to develop biosimilar productions and promote National Health Insurance schemes, high-cost medical care benefit programs and other reimbursements which will improve the use of biopharmaceuticals which in turn increases the market size of biopharmaceuticals/biosimilars.
- The government of Japan provides feasible procedures to market biopharmaceuticals by offering opportunities such as minimizing clinical trial, ease in drug approval procedure, subsidies, and tax incentives for new investments.
- Japan Government also created multiple bio-clusters for R&D cost reduction.
LIFE SCIENCES MARKET
- Major sub-segments in Japan life sciences market include pharmaceutical and medical device market. Japan ranks second in life sciences markets after the United States.
1. Market Size and Growth Rate
- According to the International Trade Administration, in 2017, the Japanese pharmaceuticals market size was around $95 billion.
- The Japanese pharmaceuticals market has a growth rate of 3.3% from 2017 to 2022.
- In 2018, Japanese medical device market was $54.5 billion and is projected to reach $74.7 billion in 2025 with a CAGR of 4.6%.
- Major medical devices include pacemakers, orthopedic implants, and PTCA catheters.
2. Growth Factors and Opportunities
- There is an increase in the number of chronic diseases among Japan's aging population (25%). This is acting as one of the prominent growth factors and paving way for opportunities in pharmaceuticals and medical device market.
- Japanese government initiatives such as streamlining regulatory approval, quick review process, reimbursement system, National Strategic Special Zones, tax benefits are enhancing the opportunity for life sciences companies in Japan.